Athens Bioscience, Inc., a manufacturer of native human and animal proteins for the global life sciences industry, today announced the launch of its immunogen-grade protein product line. The new line offers proteins purified up to 99% target-protein content, with purity and composition independently verified by LC-MS/MS on a high-resolution Orbitrap mass spectrometry platform—a level of analytical validation that the company says is unprecedented for commercially available native protein immunogens.
Immunogen quality is a foundational variable in antibody development. When researchers immunize animals to generate polyclonal or monoclonal antibodies, contaminants present in the immunogen can elicit off-target immune responses, producing non-specific antibodies that compromise downstream assay performance. Similar quality requirements apply to manufacturers developing calibrators, controls, and reference standards, where the composition of the starting material directly affects the accuracy of the finished product.
Despite these requirements, the term “immunogen-grade” has lacked a consistent industry definition. Many commercially available proteins labeled as immunogen-grade are characterized only by SDS-PAGE—a method that cannot distinguish between co-migrating proteins of similar molecular weight and provides no information about the identity of minor contaminants.
“We kept hearing the same concern from customers developing antibodies and building calibrator panels: they needed to know exactly what was in the vial before they committed it to an immunization protocol or a reference standard,” said Karson Durie, PhD, Lab Director at Athens Bioscience. “With SDS-PAGE alone, you can see that a preparation looks clean, but you can’t confirm the identity of every component. Our immunogen-grade line was built to close that gap.”
Compositional Transparency Through Mass Spectrometry
Each immunogen-grade lot is analyzed by LC-MS/MS, with data searched against the UniProt human proteome database at a 1% false discovery rate. The resulting compositional profile reports the identity and relative abundance of every detectable protein in the sample, including the target protein, any subclass distribution where applicable, and any trace co-purified proteins—each identified by name and quantified by relative signal intensity.
For immunoglobulin products—the largest category in the immunogen-grade line—this analysis provides subclass-level detail. A lot of IgG Fc fragment, for example, ships with a compositional breakdown showing the relative abundance of IgG1, IgG2, IgG3, and IgG4 Fc, along with any trace immunoglobulin or light chain content. This level of characterization is particularly relevant for manufacturers developing subclass-specific diagnostic assays or calibrators that require defined composition.
“The analytical method matters as much as the purification,” Durie added. “Two proteins within a few kilodaltons of each other will co-migrate on an SDS-PAGE gel and appear as a single band. Mass spectrometry resolves those components individually. That’s the difference between reporting purity by appearance and reporting purity by composition.”
Applications Across Antibody Development and Diagnostics Manufacturing
The immunogen-grade line initially spans the company’s immunoglobulin portfolio, including IgG, IgA, IgM, IgD, and IgE from human plasma and myeloma sources, as well as immunoglobulin fragments (Fc, Fab, Fab’2, light chain) and species-specific variants. Athens Bioscience plans to extend immunogen-grade designation to additional protein families based on customer demand.
Target applications include polyclonal and monoclonal antibody generation, development of calibrators and controls for immunoassay platforms, qualification of reference standards, and any research application where immunogen composition is a critical variable.
“The immunogen-grade line represents a natural extension of how we’ve always approached protein manufacturing—start with rigorous purification, then verify the result with the best available analytical tools,” said John Mitchell, Chief Executive Officer of Athens Bioscience. “Our customers are building products and generating data that depend on the quality of their starting materials. This product line gives them the documented confidence to move forward.”
Immunogen-grade products are available immediately through the Athens Bioscience website and through the company’s global distributor network. Each lot ships with a Certificate of Analysis that includes the full LC-MS/MS compositional profile, lot-specific SDS-PAGE with quantitative densitometry, and measured purity values. Raw analytical data is available on request.
About Athens Bioscience
Athens Bioscience, Inc. (formerly Athens Research & Technology, Inc.) manufactures native human and animal proteins for the global life sciences industry. Founded in 1986 and headquartered in Athens, Georgia, the company serves IVD manufacturers, cell culture media companies, pharmaceutical researchers, and academic institutions worldwide. For more information, visit www.athensbioscience.com.